69 studies found for:    Alkermes
Show Display Options
RSS Create an RSS feed from your search for:
Alkermes
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults
Condition: Alcoholism
Interventions: Drug: Medisorb naltrexone 380 mg;   Drug: Medisorb naltrexone 190 mg
2 Completed
Has Results
ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)
Condition: Alcohol Dependence
Interventions: Drug: Medisorb naltrexone 190 mg;   Drug: Medisorb naltrexone 380 mg
3 Recruiting A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
Condition: Healthy
Interventions: Drug: Moxifloxacin;   Drug: ALKS 5461;   Drug: Placebo
4 Recruiting A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
Condition: Healthy
Interventions: Drug: ALKS 5461;   Drug: Buprenorphine;   Drug: Placebo
5 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
6 Recruiting A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Conditions: Schizophrenia;   Alcohol Use Disorder
Interventions: Drug: Samidorphan + olanzapine (ALKS 3831);   Drug: Placebo
7 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
8 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Condition: Major Depressive Disorder
Interventions: Drug: High Dose ALKS 5461;   Drug: Low Dose ALKS 5461;   Drug: Placebo
9 Completed A Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Samidorphan (Low Dose);   Drug: Samidorphan (Medium Dose);   Drug: Samidorphan (High Dose);   Drug: Placebo;   Drug: Olanzapine
10 Completed A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil or ALKS 9070) in Subjects With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ALKS 9072;   Drug: Placebo
11 Active, not recruiting An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole Lauroxil
12 Completed A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461
13 Completed A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users
Condition: Healthy Volunteers
Interventions: Drug: Samidorphan;   Drug: Placebo;   Drug: Oxycodone
14 Completed A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
Condition: Multiple Sclerosis
Interventions: Drug: Study Drug;   Drug: Active Control;   Drug: Placebo
15 Terminated
Has Results
ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])
Conditions: Alcoholism;   Opiate Dependence
Interventions: Drug: Medisorb naltrexone 380 mg;   Drug: Oral naltrexone to Medisorb naltrexone 380 mg
16 Recruiting Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
Condition: Hepatic Impairment
Intervention: Drug: ALKS 5461
17 Completed ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
Condition: Opioid-induced Constipation
Interventions: Drug: ALKS 37;   Drug: Placebo
18 Completed ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
Condition: Opioid-induced Constipation
Interventions: Drug: RDC-1036 (ALKS 37);   Drug: Placebo
19 Completed
Has Results
ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
Condition: Opiate Dependence
Intervention: Drug: Medisorb naltrexone 380 mg
20 Recruiting A Long-Term Safety Study of ALKS 5461
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years